Aptevo Therapeutics Inc. Repayments of Long-Term Debt
Aptevo Therapeutics Inc. (APVO) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2025-02-14
- Aptevo Therapeutics Inc. repayments of long-term debt for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Aptevo Therapeutics Inc. repayments of long-term debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Aptevo Therapeutics Inc. repayments of long-term debt for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Aptevo Therapeutics Inc. repayments of long-term debt for the quarter ending 2023-03-31 was $3.47M, a 67.80% decline year-over-year.
- Aptevo Therapeutics Inc. repayments of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Aptevo Therapeutics Inc. repayments of long-term debt for fiscal 2023 was $3.47M, a 71.74% decline from fiscal 2022.
- Aptevo Therapeutics Inc. repayments of long-term debt for fiscal 2022 was $12.27M, a 16.27% increase from fiscal 2021.
- Aptevo Therapeutics Inc. repayments of long-term debt for fiscal 2021 was $10.55M, a 52.27% decline from fiscal 2020.
| Period end | Repayments of Long-term Debt | Repayments of Long-term Debt 1 month | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-14 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $0.00 derived: sum of 2 quarters · filed 2025-02-14 | $0.00 derived: sum of 3 quarters · filed 2025-02-14 | $3.47M 10-K · filed 2025-02-14 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $3.47M 10-Q · filed 2024-11-07 | $3.97M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.47M 10-Q · filed 2024-08-08 | $3.97M derived: sum of 3 quarters · filed 2024-08-08 | $4.47M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $3.47M 10-Q · filed 2024-05-08 | $3.97M derived: sum of 2 quarters · filed 2024-05-08 | $4.47M derived: sum of 3 quarters · filed 2024-05-08 | $4.97M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.00M derived: sum of 2 quarters · filed 2024-03-05 | $1.50M derived: sum of 3 quarters · filed 2024-03-05 | $12.27M 10-K · filed 2024-03-05 | ||
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.00M derived: sum of 2 quarters · filed 2023-11-14 | $11.77M 10-Q · filed 2023-11-14 | $11.77M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $11.27M 10-Q · filed 2023-08-10 | $11.27M derived: sum of 3 quarters · filed 2023-08-10 | $11.27M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $10.77M 10-Q · filed 2023-05-11 | $10.77M derived: sum of 2 quarters · filed 2023-05-11 | $10.77M derived: sum of 3 quarters · filed 2023-05-11 | $10.77M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $10.55M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $10.55M 10-Q · filed 2022-11-10 | $10.55M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $10.55M 10-Q · filed 2022-08-11 | $10.55M derived: sum of 3 quarters · filed 2022-08-11 | $10.55M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $5.00M 10-Q · filed 2022-11-10 | $10.55M 10-Q · filed 2022-05-12 | $10.55M derived: sum of 2 quarters · filed 2022-05-12 | $10.55M derived: sum of 3 quarters · filed 2022-05-12 | $10.55M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2021-03-30 | $5.00M 10-K · filed 2023-03-30 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $0.00 derived: sum of 2 quarters · filed 2022-03-24 | $0.00 derived: sum of 3 quarters · filed 2022-03-24 | $22.10M 10-K · filed 2022-03-24 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $22.10M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $22.10M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | $22.10M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |